The contribution of recent infections to HIV-1 transmission clusters in the UK. 18th International HIV Dynamics and Evolution Conference, 1-4 May 2011.. 2011.
Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis. AIDS. 30(3). 2016.
The impact of resistance testing in ARV-naive patients: does it guide optimal therapy selection and improve long-term outcomes? British HIV Association 14th Annual Conference, 23-25 April 2008.. 2008.
The impact of HIV drug resistance testing on changes to treatment. AIDS. 25:603-10.. 2011.
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). J Acquir Immune Defic Syndr. 53:633-9.. 2010.
Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Chemother. 67:995-1000.. 2012.
Prevalence and predictors of protease inhibitor (PI) mutations in HIV-infected UK adults treated with ritonavir-boosted lopinavir as their first PI. 17th Annual Conference of the British HIV Association, 6-8 April 2011.. 2011.
Protease mutations emergining on darunavir in protease inhibitor-naive and experienced patients in the UK. International Congress of Drug Therapy in HIV Infection, November 2014.. 2014.
The Prevalence of Darunavir Associated Mutations in PI-naive and PI-experienced HIV-1 Infected Children in the UK. 17th Conference on Retroviruses and Opportunistic Infections, February 2010.. 2010.
How common is the mutation E138K in the UK? 18th Annual Conference of the British HIV Association, 18-20 April 2012.. 2012.
The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. J Infect. 68:77-84.. 2014.
The emergence of drug resistant HIV variants at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine within the UK CHIC cohort. 18th Annual Conference of the British HIV Association, 18-20 April 2012.. 2012.
Antiretroviral drug resistance in pregnant women living with HIV in England and Wales: Preliminary results from the matching of three national HIV surveillance databases. British HIV Association Conference (BHIVA) 2015.. 2015.
Detection of NNRTI resistance mutations after interrupting NNRTI-based regimens. Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014.. 2014.
Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS. 21:447-55.. 2007.
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 331:1368.. 2005.
Persistence of transmitted HIV drug resistance mutations. International Workshop on HIV & Hepatitis Virus Resistance and Curative Strategies, 5-9 June 2012. Antiviral Therapy 17 Suppl 1:A167.. 2012.
Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance. BMC Med Res Methodol. 12:30.. 2012.
Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 208:1459-63.. 2013.